No treatment has been found which reverses long-standing neurological dysfunction in patients with multiple sclerosis (MS). Observations in animal models of MS show that immunoglobulins directed against CNS components promote oligodendroglial proliferation and new myelin synthesis. Preliminary studies in inflammatory-demyelinating diseases of the human peripheral and central nervous system suggest that the repeated intravenous administration of polyclonal human immunoglobulin (IVIg) is sometimes followed by clinical improvement. A randomised, placebo-controlled, doubleblind, clinical trial was designed to test the hypothesis that repeated administration of IVIg will result in a meaningfiu degree of recovery of apparently irreversibly lost neurological function (weakness). A total of 76 patients with MS will participate in the study. These patients had developed a fixed, apparently permanent weakness that had not improved in the preceding four to 18 months. If effective, IVIg administration may benefit the large proportion of patients with MS who have active disease by enhancing the potential for myelin repair in the evolution of the inflammatory-demyelinating lesion.
The precise mechanisms by which TMEV induces demyelination is unknown. Because TMEV injures oligodendrocytes, cytopathological injury to oligodendrocytes may result in demyelination.12 13 The observation that nude mice develop demyelination following TMEV infection indicates that T-cells are not required for the initiation of demyelination.14 In addition, there is considerable evidence implicating an immune-mediated mechanism underlying TMEV-induced demyelination. The inflammatory infiltrate is closely associated morphologically with areas of demyelination.'0 Immunosuppression with cyclophosphamide, anti-lymphocyte serum, cyclosporine and monoclonal antibodies (mAbs) to class II MHC products reduces the extent of demyelination. [15] [16] [17] [18] Both class Irestricted and class II-restricted T-cells appear to be important in the late phases of TMEV-induced demyelination. In vivo therapy with mAbs directed against class Irestricted CD8+ T-cells or class II-restricted CD4+ T-cells suppresses the extent of demyelination. '9 20 Administration of emulsions of myelin basic protein plus 
Possible mechanisms of action of IVIg
The mechanisms of action of IVIg in the few diseases for which it has proven efficacy are only partially understood. These include saturation of Fc receptors on reticuloendothelial cells (acute autoimmune thrombocytopenic purpura of childhood"3-32) and B and T cells resulting in modulation of the immune response,"-'4 reduced natural killer cell activity (autoimmune idiopathic thrombocytopenic purpura and autoimmune neutropenia35), and neutralisation of putative autoantibodies by naturally occurring antiidiotypic antibodies within the IVIg preparation. 36 37 The mechanism by which polyclonal IgG promotes remyelination and glial cell proliferation in the Theiler's virus model is unknown. As discussed above, it is proposed that there may be antibodies within the anti-SCH serum that stimulate progenitor glial cell proliferation following binding to a cell surface receptor responsible for growth or differentiation. These mechanisms are known to occur in other examples of autoimmunity.3842
Mayo clinic randomised trial of IVIg therapy in multiple sclerosis We are currently completing an open-label, pilot study of IVIg in 10 patients with MS using a protocol identical to the proposed fullscale clinical trial (with the exception of the placebo-controlled limb). This pilot study has allowed us to assess the safety of IVIg in this subset of patients with MS, to assess the adequacy of our proposed adverse effects surveillance mechanisms, and to gain experience with the treatment and outcome measurement methods to be used in the controlled trial.
The overall goal of this randomised, double-blind and placebo-controlled clinical trial is to determine whether IVIg administration is followed by clinical improvement of apparently irreversibly lost motor function (muscle strength) in patients with MS. This trial differs from other prospective MS clinical trials because we are attempting to assess whether experimental treatment results in clinical improvement rather than delay or prevention of further progression. Inclusion criteria: Patients must have clinically definite43 or laboratory supported definite MS44 which has been either relapsing-remitting or relapsing-progressive (secondary progressive) from onset. Patients must be between the ages of 18 and 60 and have a fixed, apparently irreversible, motor deficit ("targeted neurological deficit"): weakness of at least one limb which has been documented in the Departrnent of Neurology at the Mayo Clinic to have been present and static for four and 18 months).
Patients must not have received ACTH, immunosuppressive therapy, corticosteroids, or plasma exchange within the preceding three months. The observed duration of the fixed neurological motor deficit was chosen to minimise the likelihood of delayed, spontaneous, unexpected and possibly placeborelated recovery of the 'targeted neurological deficit'.45 
